Skip to content

Clinical trial of absorbable composite screw

Clinical trial of absorbable composite screw

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000030735
Enrollment
Unknown
Registered
2020-03-12
Start date
2019-06-22
Completion date
Unknown
Last updated
2020-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Internal fixation, osteotomy and arthrodesis of various non bearing parts

Interventions

Experimental group:Use the absorbable composite screw produced by Chengdu Dikang biomedical materials Co., Ltd
control group:Use the absorbable bone screws produced by Changchun Shengboma Biological Materials Co.,Ltd.

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) The subject or guardian is willing and able to sign the informed consent; 2) Aged 18-65 years; 3) Fresh fracture patients; 4) Patients who need internal fixation, osteotomy and arthrodesis of non load bearing fracture; 5) Good compliance, willing and able to follow up as required.

Exclusion criteria

Exclusion criteria: 1) Local infection of the whole body or operation site; 2) Patients with osteomyelitis; 3) Pathological fracture of operation site; 4) Fracture with osteofascial compartment syndrome; 5) Metabolic osteopathy (except osteoporosis in the elderly); 6) Patients with malignant tumor; 7) Severe multiple injuries (with severe brain injury or multiple organ injury, etc.); 8) Patients who are systematically using corticosteroids; 9) Patients using growth factors; 10) Long term use of sedative and hypnotic drugs (continuous use for more than 3 months); 11) Long term use of non steroidal anti-inflammatory drugs (continuous use for more than 3 months); 12) Those who are allergic to the materials used in the product; 13) Lactating or pregnant women; 14) Mental illness, drug abuse, alcoholism; 15) Severe heart, liver, kidney, lung, blood system and other diseases can not tolerate surgery; 16) Subjects participated in other clinical studies 3 months before selection; 17) Other situations in which patients are not considered suitable for this study.

Design outcomes

Primary

MeasureTime frame
Fracture healing rate at 6 months after operation;

Secondary

MeasureTime frame
Efficiency of comprehensive evaluation;Fracture healing rate at 6 weeks and 12 weeks after operation;Performance evaluation of the product during operation;

Countries

China

Contacts

Public ContactChangqing Zhang

Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai

zhangcq@sjtu.edu.cn+86 18930177335

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026